XIAP Deficiency

Clinical trial pipeline · Data from ClinicalTrials.gov

See which XIAP Deficiency trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT07433621

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a…

United States12 participantsStarted 2026-02-26

Treatment: Quercetin

All recent trials (6 shown)

Active — Not RecruitingPhase 2

NCT04641442

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammato…

This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC…

United States17 participantsStarted 2020-12-18

Treatment: MAS825, Placebo

CompletedPhase 3

NCT03113760

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

This is a Phase 3 study to assess the safety and efficacy of Tadekinig alfa in patients with monogenic, interleukin-18 (IL 18) driven autoinflammation due to Nu…

United States15 participantsStarted 2017-07-21

Treatment: Tadekinig alfa, 0.9% sodium chloride

XIAP Deficiency

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

All recent trials (6 shown)

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammato…

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

All recent trials (6 shown)

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammato…

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

Study of Gut Microbiota in Primary Immune Deficiency, Possibly Associated With Inflammatory Bowel Disease